Pfizer Oncology is striving to cure or control cancer with breakthrough medicines. Compounds under evaluation are across four scientific platforms — anti-angiogenesis, signal transduction, cell cycle, and metabolism — and multiple tumor types. Guided by the principles of precision medicine and working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, licensing partners, and other partners, we aim to deliver the right drug at the right time for each patient.
Oncology is a core area of research focus for Pfizer. Our Oncology Research Unit and Business Unit work in seamless partnership, with a mutual commitment to delivering highly innovative and commercially viable cancer therapies. In order to fulfill this commitment, we are continuously managing and refining our dynamic portfolio, which includes deciding which compounds to develop internally and which may be candidates for continued development through partnerships. At the same time, we are looking to complement our internal portfolio with compounds in early clinical development, those that have achieved proof of concept in randomized controlled multicenter phase 2 trials and phase 3 programs. We are seeking greater depth and breadth in key disease areas in our late-stage portfolio — renal cell carcinoma, lung cancer, hematologic malignancies, and breast cancer — while also looking to develop breakthrough medicines in other areas of unmet need. In addition, our Oncology Research Unit is focused in established areas such as cell signaling, and emerging areas of cancer biology, including tumor metabolism, epigenetics and antibody-drug conjugates (ADCs), a highly promising therapeutic modality that provides targeted delivery of an antibody drug linked to chemotherapy.
Areas of Interest
- Late-stage assets in phase 2 and phase 3 (in randomized multi-center controlled clinical trials)
- Highly differentiated assets which raise standard of care via clinically meaningful improvement in efficacy and/or safety
- Focus on assets which fit a precision medicine strategy
- Programs which include biomarkers that enable asset to provide significant benefit to targeted patient subset
- Tumor areas of interest: Hematology, Lung, Breast, Renal Cell Carcinoma (Kidney)
- Currently excluding cytotoxics, radiotherapies, supportive care and devices